MCDONNELL DOUGLAS FINANCE CORP /DE
424B3, 1994-01-05
FINANCE LESSORS
Previous: PUTNAM HEALTH SCIENCES TRUST, 497J, 1994-01-05
Next: MCDONNELL DOUGLAS FINANCE CORP /DE, 424B3, 1994-01-05




                                                             Filed Pursuant to
								Rule 424(b)(3)
							     File No. 33-31419


                               PRICING SUPPLEMENT DATED
                            January 4, 1994 TO PROSPECTUS
                               DATED November 18, 1993

                        McDONNELL DOUGLAS FINANCE CORPORATION

                             Series IX Medium-Term Notes
           Interest payable Semi-annually on March 15th and September 15th
                                   and at maturity

            Except as set forth herein, the Series IX Medium-Term Notes
       offered hereby (the "Notes") have such terms as are described in the
       accompanying Prospectus dated November 18, 1993.

       Aggregate Principal Amount:   $ 15,000,000 

       Original Issue Date 
        (Settlement Date):           January 5, 1994 

       Stated Maturity Date:         December 28, 1998

       Issue Price:                  100.00% of Principal Amount

       Interest Rate:                6.35% Per Annum

       Interest Payment Dates:       March 15 and September 15 commencing
                                     March 15, 1994

       Type of Notes Issued:         [  X] Senior Notes
                                     [   ] Subordinated Notes

       Optional Redemption:          [  ] Yes
                                     [  X] No

       Form of Notes Issued:         [  X] Book-Entry Notes
                                     [   ] Certificated Notes


       CUSIP Number:                 58017DCM0


       AGENT

           The Notes being offered hereby are being offered through Merrill
       Lynch, Pierce, Fenner & Smith Incorporated (doing business as Merrill
       Lynch & Co.) ("Merrill"), as Agent.  Net proceeds payable to McDonnell
       Douglas Finance Corporation (the "Company") will be 99.936% of the
       aggregate principal amount of the Notes, or $14,990,400, before
       deduction of expenses payable by the Company.  In connection with the
       sale of the Notes, Merrill will receive a commission from the Company
       in the amount of .064% or $9,600.

       OTHER INFORMATION

           The information in the Prospectus set forth under the caption
       "RISK FACTORS-Relationship with MDC" is supplemented by the following:
<PAGE>
           MDC has accepted, with clarifications, a proposal from the
	   Department of Defense on an overall business settlement of a
	   variety of issues concerning the C-17 program.  In connection with
           the settlement, MDC expects to record a charge to pre-tax earnings
           of approximately $450 million in the fourth quarter of 1993.  The
           settlement is not expected to result in a significant adverse cash
           impact to MDC.  MDC and the U.S. Air Force will be developing
           plans, contractual modifications and agreements to implement the
           business arrangement, which is subject to congressional
           authorization and appropriations.

           The U.S. Navy has advised MDC and General Dynamics Corporation
           ("GD") that the 1993 review of the deferment agreement between
           MDC, GD and the Navy with respect to the A-12 aircraft is
           continuing, in particular with respect to the impact of the C-17
           settlement between the Government and MDC described in the
           preceding paragraph.  The Navy has stated that MDC and GD will be
           advised of the results of the review and any action that may be
           taken by the Government on or about February 4, 1994.  MDC and GD
           also were advised that this timing does not suggest any adverse
           implication for the outcome of the review.  MDC firmly believes it
           is entitled to have the deferment agreement continued and did not
           agree to the Navy's unilateral continuation of the review.


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission